CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · IEX Real-Time Price · USD
53.12
-0.84 (-1.55%)
At close: Jul 2, 2024, 4:00 PM
53.37
+0.25 (0.48%)
After-hours: Jul 2, 2024, 7:47 PM EDT
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for CRSP stock have an average target of 80.29, with a low estimate of 30 and a high estimate of 160. The average target predicts an increase of 51.16% from the current stock price of 53.12.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRSP stock from 20 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Hold | 7 | 9 | 9 | 7 | 8 | 9 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 21 | 21 | 18 | 19 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jun 28, 2024 |
| Needham | Needham | Strong Buy Reiterates $88 | Strong Buy | Reiterates | $88 | +65.68% | Jun 27, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $105 | Buy | Reiterates | $105 | +97.68% | Jun 17, 2024 |
| Needham | Needham | Strong Buy Reiterates $88 | Strong Buy | Reiterates | $88 | +65.68% | Jun 17, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $89 → $84 | Strong Buy | Maintains | $89 → $84 | +58.15% | May 23, 2024 |
Financial Forecast
Revenue This Year
64.45M
from 371.21M
Decreased by -82.64%
Revenue Next Year
341.32M
from 64.45M
Increased by 429.61%
EPS This Year
-5.74
from -1.94
EPS Next Year
-4.64
from -5.74
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 481.3M | 3.5B | 5.7B | 8.3B | 12.3B |
| Avg | 64.4M | 341.3M | 871.6M | 1.5B | 2.2B |
| Low | 490,000 | n/a | 88.2M | 102.9M | 117.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.7% | 5,295.0% | 1,574.4% | 851.7% | 740.2% |
| Avg | -82.6% | 429.6% | 155.4% | 67.6% | 47.2% |
| Low | -99.9% | - | -74.2% | -88.2% | -92.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.74 | 5.29 | 8.99 | 13.10 | 27.84 |
| Avg | -5.74 | -4.64 | -1.43 | 0.97 | 4.87 |
| Low | -7.09 | -8.54 | -6.42 | -5.34 | -4.17 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 2,769.3% |
| Avg | - | - | - | - | 402.0% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.